Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...

Novo Nordisk NVO shares have climbed 10% in the past month, supported by a mix of certain internal factors and positive market catalysts, which boosted investor confidence. In early September, Novo ...

Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...

Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and ...

Novo Nordisk is set to lay off roughly 9,000 employees across its global workforce of 78,400 as part of a newly launched restructuring initiative. In a Sept. 10 press release, the Danish ...